**Core tip:** Pelvic exenteration (PE) for locally advanced primary rectal cancer (LAPRC) is associated with high rates of perioperative adverse events, but the survival benefit obtained when R-ve margins are achieved outweighs this risk. In low LAPRC, PE achieved better pathologic outcomes, resulting in a trend towards reduced LR compared with non-exenterative procedures.

INTRODUCTION
============

Colorectal cancer is the fourth cause of cancer-related death in United States\[[@B1]\]. A recent analysis of the SEER programme concerning age-specific annual percent change in incidence rates from 2000 to 2013 showed that the incidence of rectal cancer and advanced disease has slightly decreased, but it is less than that of colon cancer\[[@B2]\]. Five-year survival is influenced by tumour stage, ranging from 90% in cancer confined to the primary site and 71% in those with local node involvement to 14% in Stage IV\[[@B3]\]. One-third of newly diagnosed rectal cancers in the United Kingdom will be locally advanced at the time of diagnosis, accounting for more than 4600 cases of cancer per year\[[@B4],[@B5]\].

Recent advances in the multimodal management of patients with rectal cancer invading local structures have led to an increase in the rate of patients amenable to receive surgery along the anatomical planes after neoadjuvant treatment. Nevertheless, a relatively high number of patients might still be found with tumours invading surrounding organs\[[@B4]\].

Pelvic exenteration (PE) is a technically demanding procedure involving "*en-bloc*" excision of the rectum and adjacent invaded organs, aiming at obtaining disease-free resection margins. Over time, contraindications to such a demolitive approach have been gradually reduced as a result of perioperative patient conditioning, increased surgical experience, and postoperative multidisciplinary management\[[@B5]-[@B7]\]. Surgery beyond the total mesorectal excision (TME) plane and involving sacrifice of other pelvic organs for locally recurrent or advanced rectal cancer has been analogous to a "sarcoma-like" procedure\[[@B6],[@B8]-[@B10]\], during which several surgical teams and specialties need to be involved. PE for rectal cancer brings higher risks of complications, ranging from 25% to 42%\[[@B5],[@B8],[@B11]\], with studies reporting higher rates when PE for other-than-rectal cancers is included\[[@B12]\]. The high incidence of complications is downplayed by the survival benefits obtained by excision of the pelvic mass with microscopically negative margins (R0)\[[@B7],[@B8],[@B12]-[@B14]\]. Few studies have focused on the outcomes of PE in locally advanced primary rectal cancer (LAPRC), although an increasing number of patients are being offered this extensive procedure. A recent study of the PelvEx Collaborative found that the median life expectancy after curative PE for LAPRC surpasses 40 mo, but median survival after resections with macroscopically involved margins drops to less than one year\[[@B14]\].

As part of a national quality improvement programme in the treatment of rectal cancer, the Spanish Association of Surgeons \["Asociación Española de Cirujanos" (AEC)\] started an online database\[[@B15]\] in which all primary rectal cancers were prospectively included on a voluntary basis. Data on patients undergoing PE were also recoded.

The aims of this study are to assess the short- and long-term outcomes of PE for primary LAPRC in patients included in the AEC registry and to compare the oncologic results of PE with a matched group of patients treated with non-exenterative TME during the study timeframe.

MATERIALS AND METHODS
=====================

This study complies with the STROBE statement for observational studies\[[@B16]\] (Flowchart in Supplementary Figure 1; checklist available as uploaded STROBE Statement). In 2006, the AEC established a national audit project to improve the outcomes of rectal cancer surgery. The project was named "Viking" because it was inspired by the project from Norway\[[@B17]\] and followed the same principles\[[@B18]\]. Between 2006 and 2017, 105 Spanish hospitals joined the online registry, with over 18000 patients included. The aim of this study was to assess morbidity and long-term outcomes of PE for LAPRC.

Inclusion and exclusion criteria
--------------------------------

We included patients who underwent PE for LAPRC between 2006 and 2017. The patients were only included if they underwent surgery with curative intent. For the survival analysis, only patients with a minimum follow up of 5 years were evaluated.

The patients who were unfit for surgery, those who underwent palliative surgery, those diagnosed with other malignancies besides colonic malignancies, and those with unsatisfactory information were excluded from the analysis.

Endpoints and definitions
-------------------------

The primary aims of this study were: (1) short-term morbidity and mortality of PE for LAPRC; (2) overall 5-year local recurrence (LR), disease-free survival (DFS), and overall survival (OS). Secondary outcomes included oncologic outcomes after PE compared with patients in the registry who underwent TME for distal rectal cancer surgery during the same timeframe, with a propensity-matched analysis.

The online database allows the investigators to classify the type of intervention performed. Only "PE" interventions were included in the analysis and consisted of either posterior (removal of rectum, internal genital organs in female) or total (removal of rectum and bladder, in male and female). Indications for surgery and perioperative management were not standardized before starting the study, although most centres followed the agreed-upon criteria\[[@B19]\].

Thirty-day complications were collected, and the responsible collaborator at each centre updated the data on oncologic outcome yearly\[[@B18],[@B20]\].

Specimen assessment and reporting have been previously described\[[@B18],[@B20],[@B21]\]. Briefly, margins were considered tumour-free if no microscopic involvement was seen at pathology. The circumferential resection margin was considered involved if cancer cells were found 1 mm or less from the margin\[[@B20]\]. The quality of the mesorectum and abdominoperineal excision was scored using three grades as described by others\[[@B20]-[@B23]\].

LR was defined as a mass near or at the same place as the original tumour, after a period of time in which the tumour was not detected. LR was included only if an imaging exam proved the recurrence combined with raised CEA.

DFS was defined as time to develop a distant disease relapse that was not present or suspected at primary surgery. Distant metastases included para-aortic and inguinal nodes.

OS was defined as time to death for any reason.

Detailed definitions and scope of the registry have been previously reported\[[@B15],[@B18],[@B20]\] (<http://www.aecirujanos.es/images/stories/recursos/secciones/coloproctologia/2015/proyecto_vikingo/documentos/definiciones_proyecto_vikingo.pdf>).

For the secondary aims, the group that was propensity matched with PE included all patients from the database with low rectal cancer who underwent TME surgery with abdominoperineal excision, extralevator abdominoperineal excision, and low anterior resection between March 2006 and December 2013.

Statistical analysis
--------------------

Continuous variables are reported as the means ± standard deviations (SD), and categorical variables are reported as the numbers with percentages (%).

For the secondary aims, the propensity-matched analysis for complications was carried out based on the following variables: American Society of Anesthesiologists' (ASA) score, neoadjuvant treatment, and pT stage. Only patients with cancer of the lower third of the rectum (0-6 cm from anal verge) who underwent curative TME surgery were included.

Categorical variables were compared with Fisher's exact test and Chi square test as appropriate, whereas continuous variables were compared with Mann-Whitney *U* test.

Kaplan-Meier survival curves were generated to assess 5-year survival, and log rank test was used for comparisons when applicable. Cox regression analysis was used to identify predictors of LR, DFS, and OS, including the following variables: resection margin status, quality of mesorectum, neoadjuvant treatment, adjuvant treatment, and perioperative complications. The results are reported as hazard ratio (HR) with 95% confidence intervals (95%CI). HR \> 1 is associated with increased risk. Patients lost at follow up were classified as censored.

*P* values \< 0.05 were considered statistically significant. The Statistical Package for Social Sciences (SPSS version 24.0.0; IBM SPSS statistics, IBM Corporation, Armonk, NY) was used for the descriptive analyses.

RESULTS
=======

We analysed data on 82 patients undergoing PE for LAPRC in 33 hospitals, with a mean number of procedures per hospital of 2.5 ± 3.1 overall.

Baseline patient characteristics and surgical details
-----------------------------------------------------

Demographics and perioperative features are summarized in Table [1](#T1){ref-type="table"}. The mean age of the patients was 61.8 ± 11.5 years, 65.9% were men, 34.1% were women, and 45.1% were classified as ASA ≥ III. Most patients were staged as MRcT4 \[T4 with magnetic resonance (MR)\] and had extensive nodal involvement. The tumour was located in the proximal third of the rectum (15-11 cm) in 18 (22%) patients, in the middle third (10-7 cm) in 31 (37.8%) patients, and in the distal third (6-0 cm) in 33 (40.2%) patients. Seven patients underwent PE with concomitant distant metastases. Neoadjuvant treatment was offered to 72% of patients and included radiotherapy in 93% of them. No data were available concerning time to surgery after treatment.

###### 

Demographic, preoperative, and surgical details for 82 pelvic exenterations *n* (%)

  **Variable**                      **Value**
  --------------------------------- -------------
  Age, yr                           61.8 (11.5)
  Gender                            
  Male                              54 (65.9)
  Female                            28 (34.1)
  ASA score                         
  I                                 3 (3.7)
  II                                42 (51.2)
  III                               33 (40.2)
  IV                                4 (4.9)
  Obstruction                       5 (6.1)
  MR T                              
  T3                                13 (15.9)
  T4                                56 (68.3)
  Missing                           13 (15.9)
  MR N                              
  N0                                11 (13.4)
  N1                                24 (29.3)
  N2                                35 (42.7)
  Missing                           12 (14.6)
  Sphincters involved               22 (26.8)
  Metastasis at presentation        7 (8.5)
  Neoadjuvant treatment             59 (72)
  Long course RT                    3 (5)
  Long course CRT                   41 (69.5)
  CxT                               4 (6.8)
  Short Course RT                   4 (6.8)
  CxT followed by RT                7 (11.9)
  Adjuvant treatment                54 (65.9)
  CRT                               6 (11.1)
  CT                                48 (88.9)
  Perioperative transfusions, *n*   3.4 (2)
  Anastomosis                       15 (18.3)
  Synchronous metastasis resected   4 (6.8)

Data are expressed as number of patients (%) or median (25-75 percentiles). ASA: American Society of Anaesthesiologists; CRT: Chemoradiation therapy; CxT: Chemotherapy; MR: Magnetic resonance; RT: Radiotherapy.

Fifty-four (65.9%) patients received postoperative chemotherapy, which was associated with radiotherapy in 6 (11.1%). An anastomosis was attempted in 15 patients. In the latter group, eight patients received preoperative radiotherapy and postoperative treatment was given in nine, including radiotherapy in two.

Thirty-three multivisceral resections were performed, including two hepatectomies and four metastasectomies. One liver lesion was treated with radiofrequency ablation. One patient received peritonectomy.

Primary aim: Short-term outcomes and pathology
----------------------------------------------

Perioperative death rates did not exceed 2.5%. More than half of the patients experienced at least one complication, and 10% required reoperation. Intra-abdominal septic complications occurred in 10% of the patients.

Surgical site infections affected the abdominal wound in 18.3% and the perineal closure in 19.4% of those who did not receive an anastomosis. Short-term outcomes are reported Table [2](#T2){ref-type="table"}.

###### 

Short-term outcomes *n* (%)

  **Variable**                           **Value**
  -------------------------------------- --------------
  Complications, any                     45 (54.9)
  Reoperation                            8 (9.8)
  Perioperative death                    2 (2.4)
  Sepsis                                 4 (4.9)
  Abdominal Surgical Site Infection      15 (18.3)
  Abdominal hernia                       2 (2.4)
  Perineal Wound Complications           13/67 (19.4)
  Intra-abdominal septic complications   8 (9.8)
  Injury to hollow viscera               2 (2.4)
  Ileus                                  9 (11)
  Urinary tract complications            9 (11)
  Pulmonary complications                8 (9.8)
  Neurological complications             2 (2.4)
  Multiorgan failure                     2 (2.4)
  CVC infection                          2 (2.4)
  Acute kidney failure                   2 (2.4)

Data are expressed as number of patients (%) or median (25-75 percentiles). CVC: Central venous catheter.

Table [3](#T3){ref-type="table"} depicts pathological outcomes. Most cancers were pT4b (36.6%), with significant reduction of cN2 rate in favour of pN0 (40.2%) and pN1 (20.7%). The mean number of isolated nodes was well over 12 and rarely harboured cancer (in 25.6%). Nineteen patients (23.2%) received R+ve resection - one with both circumferential and distal margins affected.

###### 

Pathological outcomes and survival *n* (%)

  **Variable**                                   **Value**
  ---------------------------------------------- -------------
  pT                                             
  Tx                                             2 (2.4)
  T0                                             1 (1.2)
  T2                                             2 (2.4)
  T3a,b                                          6 (7.3)
  T3c,d                                          13 (15.9)
  T4a                                            27 (32.9)
  T4b                                            30 (36.6)
  Missing                                        1 (1.2)
  pN                                             
  Nx                                             25 (30.5)
  N0                                             33 (40.2)
  N1                                             17 (20.7)
  N2                                             6 (7.3)
  Missing                                        1 (1.2)
  Nodes isolated                                 15.5 (10.6)
  Positive nodes                                 1.1 (0.4)
  Resection margins involved                     19 (23.2)
  Response to neoadjuvant treatment (*n* = 59)   
  Complete                                       1 (1.7)
  Islands of tumour cells                        1 (1.7)
  Predominantly fibrotic                         20 (33.9)
  Predominantly tumour nests                     21 (35.6)
  No response                                    12 (20.3)
  Missing                                        4 (6.8)
  Quality of mesorectum\[[@B20]-[@B23]\]         
  Good/complete                                  61 (74.4)
  Partially good/near complete                   9 (11)
  Bad/incomplete                                 8 (9.8)
  Missing                                        4 (4.9)

Data are expressed as number of patients (%) or median (25-75 percentiles).

Twenty percent of patients did not have any response to preoperative neoadjuvant treatment, one patient had complete pathological response (1.7%), and the remaining patients had a different spectrum of response (detailed in Table [3](#T3){ref-type="table"}). The quality of mesorectum was classified as "good" (complete)\[[@B20]-[@B23]\] in 74.4% of patients.

Primary aim: Recurrence and survival
------------------------------------

For the purpose of long-term outcomes, we excluded 18 patients who received PE after 2013, thereby analysing 64 patients.

The five-year LR was 15.6%, the distant recurrence rate was 21.9%, and OS was 67.2%, with a mean survival of 43.8 mo (Figures [1](#F1){ref-type="fig"} [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Oncologic outcomes tended to be worse in pN+ patients in all dimensions, although these differences did not reach statistical significance.

![Overall local recurrence after pelvic exenteration for locally advanced primary rectal cancer.](WJG-24-5144-g001){#F1}

![Overall disease-free survival after pelvic exenteration for locally advanced primary rectal cancer.](WJG-24-5144-g002){#F2}

![Overall survival after pelvic exenteration for locally advanced primary rectal cancer.](WJG-24-5144-g003){#F3}

The Cox regression analysis identified R+ve resection to increase the risk of LR (HR = 5.58, 95%CI: 1.04-30.07, *P* = 0.04), and partially good or bad quality mesorectum to predict shorter DFS (HR = 4.37, 95%CI: 1.02-18.65, *P* = 0.04, and HR = 6.29, 95%CI: 1.2-32.94, *P* = 0.03, respectively). Perioperative complications were independent predictors of shorter survival (HR = 3.53, 95%CI: 1.12-10.94, *P* = 0.03).

Secondary aims: Propensity-matched sub-analyses in lower rectum
---------------------------------------------------------------

The propensity match analysis identified 51 patients who received either PE (*n* = 26) or non exenterative TME (*n* = 25) for primary adenocarcinoma of the lower rectum. Patient characteristics are summarized in Table [4](#T4){ref-type="table"}. TME patients more frequently received an anastomosis (3.8% *vs* 80%, PE *vs* TME, *P* \< 0.001) and were less likely to need transfusions (*P* = 0.035). PE was associated with better quality of the specimen, consisting of fewer R+ve resections and higher rates of good quality mesorectum.

###### 

Propensity-matched analysis *n* (%)

                                               **Pelvic exenteration *n* = 26**   **Non-exenterative total mesorectal excision *n* = 25**   ***P* value**
  -------------------------------------------- ---------------------------------- --------------------------------------------------------- ------------------------------------------
  Male                                         18 (58.1)                          13 (52)                                                   0.208
  Age at surgery                               63.1 ± 8.6                         62.3 ± 13.7                                               0.794
  ASA score                                                                                                                                 0.957
  I                                            1 (3.8)                            1 (4)                                                     
  II                                           11 (42.3)                          11 (44)                                                   
  III                                          12 (46.2)                          12 (48)                                                   
  IV                                           2 (7.7)                            1 (4)                                                     
  Obstruction                                  1 (3.8)                            0                                                         0.322
  Neoadjuvant treatment                        21 (80.8)                          21 (84)                                                   0.762
  Adjuvant treatment                           19 (73.1)                          21 (84)                                                   0.343
  Anastomosis                                  1 (3.8)                            20 (80)                                                   \< 0.001[a](#T4FN1){ref-type="table-fn"}
  T Stage                                                                                                                                   0.913
  pT3a,b                                       1 (3.8)                            1 (4)                                                     
  pT3c,d                                       6 (23.1)                           6 (24)                                                    
  pT4a                                         7 (26.9)                           7 (28)                                                    
  pT4b                                         11 (42.3)                          11 (44)                                                   
  pTx                                          1 (3.8)                            0                                                         
  Resection margins involved                   5 (19)                             7 (28)                                                    0.426
  Perforation                                  2 (7.7)                            4 (16)                                                    0.357
  Transfusions                                 2.6 ± 2.4                          1.12 ± 2.4                                                0.035[a](#T4FN1){ref-type="table-fn"}
  Quality of the mesorectum\[[@B20]-[@B23]\]                                                                                                0.351
  Good/Complete                                16 (69.6)                          13 (52)                                                   
  Partially good/Nearly complete               4 (17.4)                           8 (32)                                                    
  Bad/Incomplete                               3 (13)                             4 (16)                                                    

*P*: statistically significant. ASA: American Society of Anaesthesiologists.

LR tended to be lower in patients who received PE compared with TME (*P* = 0.34) (Supplementary Figure 2), with comparable OS (*P* = 0.96) (Supplementary Figure 3).

DISCUSSION
==========

The present study showed good survival following PE for LAPRC in a cohort of patients included in a national prospective database. The procedure brings a significant risk of complications, occurring in 50% of patients, and non-negligible perioperative death rates. Pathological outcomes and long-term survival justify such extensive operations. Negative resection margins were achieved in 76.8% of patients and were associated with reduced rates of LR. Complications impaired 5-year survival. Comparing patients who underwent PE *vs* TME for low rectal cancer, PE showed a trend towards better specimen quality and lower rates of R+ve resection and tended to have longer LR-free intervals.

Since the first description of PE for gynaecologic cancer in 1948\[[@B6],[@B24]\], the procedure has been adopted with increasing success rates in patients with rectal cancer\[[@B8],[@B12]-[@B14],[@B25]-[@B27]\]. The PE of colorectal interest involves "*en bloc*" resection of the cancer and of the surrounding structures/organs, namely, the rectum, distal colon, internal reproductive organs, draining lymph in posterior PE (also known as composite resections) or bladder, lower ureters, rectum, distal colon, sacrum, reproductive organs, draining lymph nodes and peritoneum in total PE\[[@B6],[@B28]\].

Perioperative complications in our study were in line with rates reported in the literature. A systematic review\[[@B29]\] with 23 studies found that postoperative complications ranged between 37% and 100% (median 57%) and that perioperative mortality ranged between 0% and 25% (median 2.2%) after PE for LAPRC and recurrent cancer. The studies including all types of pelvic malignancies reported a complication rate as high as 64%\[[@B6]\]. In more recent series, complications occurred in 27.7% to 42.2% of patients who underwent PE for LAPRC\[[@B5],[@B11],[@B13],[@B26]\]. Irrespective of ASA score, the rate of patients developing serious complications might be similar to that observed after TME anterior resection\[[@B11],[@B30]\]. In our series, the rate of patients who developed complications needing reintervention was 10%. Surgeons willing to set up units dedicated to PE need to be prepared to long postoperative stays and significant morbidity, even in experienced hands\[[@B19]\]; early diagnosis and proactive management will be important to reduce their effects. Hsu et al\[[@B31]\] have discarded any influence of perioperative complications on survival after LAPRC surgery, but in our series, complications were independently associated with shorter life expectancy (HR = 3.53, 95%CI: 1.12-10.94, *P* = 0.03). These findings need to be carefully evaluated in the context of surgeon-specific outcomes\[[@B32]\] and learning curves associated with PE\[[@B33]\], and any attempt should be made to reduce complications, *e.g*., being very selective in performing anastomosis and including a dedicated anaesthetist in the multidisciplinary team to allow for patient optimization\[[@B5],[@B19],[@B30]\].

The rate of R+ve resection in our study was similar to other reports but likely improvable. Combined with the quality of the excised specimen, it represents a reliable surrogate marker for LR and survival after PE\[[@B6],[@B7],[@B8],[@B25]\]. The number of lymph nodes harvested in specimens from patients who underwent neoadjuvant treatment is matter of debate in the vast majority of cases, and the PelvEx collaborative found it to be significantly associated with survival\[[@B13]\]. The mean number of nodes isolated from the specimen was higher than 12, which is the minimum acceptable number for TME. However, in this series, the effect on oncologic outcome was less obvious when comparing pN+ and pN- patients. Given the importance of pT and pN status in colorectal cancer\[[@B34]\], this issue needs to be further investigated in LAPRC. We confirmed that R status was an independent predictor of LR, which was impaired by five-fold in the event of positive resection margins. Statistical significance was maintained even if we observed a wide CI; cautious interpretation is needed, but the clinical relevance is unquestioned. Kontovounisios et al\[[@B5]\] analysed the performance of dedicated PE MDT at a single unit, and they achieved an R0 rate of 93% by the last year of their report. Interestingly, there was an inverse relation between the number of referrals (increasing over time) and the relative number of procedures performed (decreasing). This outcome resulted from better patient selection and better surgical timing in the context of multidisciplinary treatment. Other series reported rates of R+ve resections similar to the one in our analysis\[[@B11],[@B13]\].

OS after PE for LAPRC is intertwined with the radicality of resection and recurrence\[[@B8],[@B13]\]. The largest international, prospective study on PE for LAPRC included 1291 patients from 14 countries and showed a median 5-year survival of 43 months. The rate of patients who were alive at 5-year follow up from our database was 67.2%, which is at or above the upper limit of the ranges reported in the literature\[[@B6],[@B12],[@B26],[@B30]\]. Reasons that could justify this finding include surgery probably not being offered to patients who might have been operated on in other centres with a more aggressive policy, *e.g*., patients with pelvic bone involvement. According to the beyond TME collaborative\[[@B19]\], only poor performance status/medically unfit patients, bilateral sciatic nerve involvement and circumferential bone involvement should be considered absolute contraindications to surgery. A more conservative approach in patients from the database appears to be a reasonable option. Another reason could be early referral to hospitals with dedicated units. Lastly, individual investigators might have decided not to include patients with more complex disease and predictable poorer outcomes.

The ideal management of patients with LAPRC arising in the lower rectum is still a matter of debate. Given the excellent results in terms of tumour clearance and quality of life achieved with TME, mutilating approaches such as PE are deemed overtreatment in many patients. However, this part of the rectum is associated with higher rates of complications, and optimizing the outcomes of surgery for LAPRC of the lower third is still matter of research\[[@B35],[@B36]\]. After adjusting two groups of patients with a propensity-matched analysis, we observed a trend towards better specimen quality and increased LR-free intervals with similar OS. These findings need further evaluation and should be considered when planning future studies on PE or involving low rectal cancers.

Limitations
-----------

This study has several limitations, and our findings should be interpreted with caution. Voluntary inclusion of patients in registries might account for a selection bias, even if they are prospective. The analysis covered a 10-year timeframe and included patients operated on different centres. Multidisciplinary patient management is crucial in PE\[[@B5]\], and variability between hospitals could not be removed. However, there are no universally agreed-upon guidelines to indicate or contraindicate PE in LAPRC, despite the latest available beyond-TME Collaborative position paper, which advocated the need for further research on the topic as a matter of priority\[[@B19]\]. No validation of the data was planned. LR was diagnosed by raising CEA associated with imaging proving recurrence, and this might have underestimated the actual incidence. Quality of life was not available in this study. Health-related quality of life and social function are of paramount importance in patients who are candidates for PE and should be considered an important endpoint of LARC surgery. The stressful experience that patients and families go through after receiving a diagnosis and when they are forced to face an advanced and aggressive disease is made even more difficult when the perspectives of the necessity of a definitive stoma (sometimes more than one) are considered. However, no dedicated questionnaires or assessments have been proposed and validated in this group of patients and should therefore be considered a research priority.

This study has strengths. Limited series of PE for LAPRC have been reported, and the findings described herein represent the second largest study with 5-year follow up available after the PelvEx Collaborative study. We suggested that patients with LAPRC of the lower third might benefit from a more aggressive surgical approach, and future studies could be designed to confirm the survival advantage in this group of patients. Some centres advocated PE in patients with liver metastases. The numbers were too small to conduct sub-analyses, and results could be misleading. Interestingly, distant metastases are usually a contraindication to PE in most referral centres\[[@B5]\]. As per the available position paper, LAPRC with metastases amenable to resection could benefit from PE, on the condition that a dedicated MDT agrees to the indication. In agreement with the statements of the beyond TME Collaborative\[[@B19]\], the outcomes of PE should be separately reported, and our manuscript only included this homogeneous group of patients.

PE is an extensive procedure with significant rate of perioperative adverse events. The analysis of a national database on LAPRC treated with PE over 10 years confirmed the survival benefit of the procedure, which overwhelms the morbidity and mortality associated with it. The rates of LR, DFS and OS were in line with most of the reported studies, but any effort should be made to improve these results (*e.g*., *via* centralization, adherence to prospective registries and auditing, dedicated training). Disease-free resection margins (R0) comprise the aim of surgery, as they predict LR. PE should be carried out in dedicated units under the care of MDT to reduce or promptly treat complications, which impair long-term survival.

Compared with non-exenterative TME surgery, PE was associated with longer disease-free intervals and achieved similar OS in patients with LAPRC for low rectal cancer.

Further studies are needed to clarify patient selection pathways and referral centre accreditation policies, and to assess quality of life after PE.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Colorectal cancer is the fourth cause of death caused by cancer according to reports from the United States. Up to 33% of rectal cancers might present as locally advanced, requiring multidisciplinary approaches. Pelvic exenteration (PE) combined with multimodal treatment has resulted in increased survival in this population of patients, but there remains a need for further reports in the literature concerning the management of patients with primary locally advanced rectal cancer.

Research motivation
-------------------

Previous studies suggested that an aggressive approach, with surgery combined with other treatment modalities, might confer good outcome in terms of tumour clearance and survival in locally advanced primary rectal cancer (LAPRC). Few reports have been published detailing the outcome of nationwide databases.

Research objectives
-------------------

This study aimed to investigate the outcome of PE for primary rectal cancer in patients included in the National Spanish Association of Surgeons Rectal Cancer Registry.

Research methods
----------------

This is a retrospective, observational study drafted according to the STROBE statement. Patients who underwent PE for LAPRC between 2006 and 2017 and who were registered in the Spanish Registry of Rectal Cancer of the Spanish Association of Surgeons were included if surgery was performed with curative intent and if 5-year follow up had been completed.

Short-term morbidity and mortality of the procedure and 5-year oncologic outcome represented the primary aims of this study. Secondary aims included a comparison of outcomes with a matched group of patients from the registry who underwent non-exenterative surgery for low rectal cancer during the same time frame.

Research results
----------------

PE were associated with perioperative mortality in approximately 2.5% of patients, and perioperative morbidity was common. More than 50% of patients had at least one complication, which required reoperation in 10%. Up to 10% of patients suffered from intra-abdominal septic complication. Wound-associated complications at the perineum were common, almost reaching 20%. The rate of resections with margins that involved tumours was 23%, and good quality of the mesorectum was achieved in 74% of specimens.

Oncologic outcome was acceptable, with good life expectancy provided a free-free resection margin had been achieved. An involved margin was independently associated with increased risk of local recurrence \[hazard ratio (HR) = 5.58, 95%CI: 1.04-30.07, *P* = 0.04\]. Survival was impaired by perioperative complications \[HR = 3.53, 95%CI: 1.12-10.94, *P* = 0.03\].

In terms of comparison with non-exenterative procedures, the latter were associated with fewer blood transfusions (*P* = 0.035) and more anastomoses (*P* \< 0.001). However, resections with involved margins were less common after PE.

Research conclusions
--------------------

PE is an extensive procedure with a significant rate of perioperative adverse events. However, our analysis of patients with LAPRC treated with this procedure over 10 years confirmed that the survival benefits justify an aggressive attitude, provided that oncologic clearance is achievable. These procedures must be performed in a dedicated unit, and patients be managed under the care of multidisciplinary teams.

Research perspectives
---------------------

An aggressive attitude could confer a significant survival gain in carefully selected patients with LAPRC. The use of national and International registries is of great value to monitor the performance of centres dealing with PE and internal auditing; therefore, their use should be encouraged.
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